Caligan Partners’s Artiva Biotherapeutics ARTV Stock Holding History
Bought
Maintained
Sold
Other funds holding ARTV
Caligan Partners's ARTV Position: Q3 2026 in Review
Caligan Partners reduced its Artiva Biotherapeutics (ARTV) stake by 15% in Q3 2026, selling an estimated $2.57M and leaving 1,481,043 shares worth $10.5M. The position accounts for 0.65% of the portfolio, ranked #23.
Caligan Partners first reported a position in ARTV in Q2 2026 and has held it in 2 quarters since. The position peaked at $16.8M in Q2 2026. 98 funds tracked by Wall St. Rank hold ARTV as of Q3 2026.
- Caligan Partners held 1,481,043 shares of Artiva Biotherapeutics worth $10.5M as of Q3 2026.
- Caligan Partners sold 255,068 Artiva Biotherapeutics shares in Q3 2026, an estimated $2.57M.
- Artiva Biotherapeutics made up 0.65% of Caligan Partners's portfolio in Q3 2026, its #23 holding.
- Caligan Partners first reported a position in Artiva Biotherapeutics in Q2 2026 and has held it in 2 quarters since.
- Caligan Partners's Artiva Biotherapeutics position peaked at $16.8M in Q2 2026.
- 98 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2026.
Based on Caligan Partners's 13F filing for Q3 2026, filed 16 Nov 2026.